Copyright (c) 2020 Mehtap Evran
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Case Report a Rare Case of Aldosteron-Secreting Giant Adrenal Carsinoma: a Case Report and Review of Literature
Corresponding Author(s) : Mehtap Evran
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 3 No. 2 (2015): 2015 Volume 3- Issue -2
Abstract
?NTRODUCT?ON
Primary aldosteronism is the most common and curable form of secondary hypertension with on estimated prevalence of 10% in referred patients, and 4% in primary care. Primary aldosteronism is presented with signs of hypertension and hypokalemia classically.
CASE PRESENTAT?ON
A 46 years old male patient was referred to our hospital with weakness, dry mouth and weight loss. He was hypertensive at out-of-office measures as grade II according to last guidelines. The patient was hospitalized to service as primer hiperaldosteronism however adrenocortical carcinoma with distant metastases was detected.
CONCLUS?ON
We presented a case of a man who had isolated aldosterone-producing adrenal cortical carcinoma. This is very rare case and also clinicians should be aware that primary hyperaldosteronism can occur in the context of adrenocortical carcinoma
Keywords
Adrenocortical carcinoma
Aldosteron
Metastasis
Hypertension
References
-
[1] Zennaro MC, Boulkroun S, Fernandes-Rosa FL. An update on novel mechanisms of primary aldosteronizm. Journal of Endocr?nology, 2014; 224(2): 63-77.
[2] Conn JW. Aldosterone in clinical medicine; post, present, and future. AMA Arch Intern Med, 1956; 97: 135.
[3] Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol, 2006; 2: 198.
[4] Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 2007; 66: 607-18.
[5] Conn JW. Presidental address. Part I: Painting background. Part II: Primary Aldosteronism, a new clinical syndrome. J Lab Clin Med, 1955; 45: 3-17.
[6] Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab, 2010; 95: 4812–22.
[7] Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol, 2011; 60: 1055–1065.
[8] Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol, 2011; 7: 323–35.
[9] Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Uro, 2003;169: 5–11.
[10] Roman S. Adrenocortical carcinoma. Curr Opin Oncol, 2006; 18: 36–42.
[11] Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3266-81.
[12] Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust N Z J Med, 1976; 6: 131-5.
[13] Schwartz GL, Turner ST. Screning for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem, 2005; 51: 386-94.
[14] Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two majör subtypes. Arch Intern Med, 1993; 153: 2125-9.
[15] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004; 136: 1227-35.
[16] Allolio B, Fassnacht M. Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.
[17] Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 2000; 88: 711.
[18] Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 4551–64.
[19] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–97.
[20] Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 192–7.
[21] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–80.
[22] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer, 2005; 12: 149–159.
References
[1] Zennaro MC, Boulkroun S, Fernandes-Rosa FL. An update on novel mechanisms of primary aldosteronizm. Journal of Endocr?nology, 2014; 224(2): 63-77.
[2] Conn JW. Aldosterone in clinical medicine; post, present, and future. AMA Arch Intern Med, 1956; 97: 135.
[3] Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol, 2006; 2: 198.
[4] Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 2007; 66: 607-18.
[5] Conn JW. Presidental address. Part I: Painting background. Part II: Primary Aldosteronism, a new clinical syndrome. J Lab Clin Med, 1955; 45: 3-17.
[6] Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab, 2010; 95: 4812–22.
[7] Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol, 2011; 60: 1055–1065.
[8] Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol, 2011; 7: 323–35.
[9] Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Uro, 2003;169: 5–11.
[10] Roman S. Adrenocortical carcinoma. Curr Opin Oncol, 2006; 18: 36–42.
[11] Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3266-81.
[12] Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust N Z J Med, 1976; 6: 131-5.
[13] Schwartz GL, Turner ST. Screning for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem, 2005; 51: 386-94.
[14] Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two majör subtypes. Arch Intern Med, 1993; 153: 2125-9.
[15] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004; 136: 1227-35.
[16] Allolio B, Fassnacht M. Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.
[17] Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 2000; 88: 711.
[18] Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 4551–64.
[19] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–97.
[20] Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 192–7.
[21] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–80.
[22] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer, 2005; 12: 149–159.
[2] Conn JW. Aldosterone in clinical medicine; post, present, and future. AMA Arch Intern Med, 1956; 97: 135.
[3] Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol, 2006; 2: 198.
[4] Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 2007; 66: 607-18.
[5] Conn JW. Presidental address. Part I: Painting background. Part II: Primary Aldosteronism, a new clinical syndrome. J Lab Clin Med, 1955; 45: 3-17.
[6] Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab, 2010; 95: 4812–22.
[7] Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol, 2011; 60: 1055–1065.
[8] Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol, 2011; 7: 323–35.
[9] Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Uro, 2003;169: 5–11.
[10] Roman S. Adrenocortical carcinoma. Curr Opin Oncol, 2006; 18: 36–42.
[11] Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3266-81.
[12] Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust N Z J Med, 1976; 6: 131-5.
[13] Schwartz GL, Turner ST. Screning for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem, 2005; 51: 386-94.
[14] Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two majör subtypes. Arch Intern Med, 1993; 153: 2125-9.
[15] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004; 136: 1227-35.
[16] Allolio B, Fassnacht M. Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.
[17] Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 2000; 88: 711.
[18] Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 4551–64.
[19] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–97.
[20] Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 192–7.
[21] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–80.
[22] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer, 2005; 12: 149–159.